Baidu
map

Oncologist:单项自评健康测量来确定老年癌症患者相关研究

2022-06-19 医路坦克 MedSci原创

超过60%的新癌症诊断发生在65岁或65岁以上的成年人中我们评估了自评健康(SRH)作为一种筛查工具来确定患有癌症的老年人的虚弱风险和GA识别的损害及其与死亡率的关系。

超过60%的新发癌症发生在65岁或65岁以上的成年人中。虽然患有癌症的老年人面临与治疗相关的风险和较低的存活率,但年龄本身并不能充分解释结果的个体差异。老年评估(GA)可以确定某些老年人在与治疗相关的不良事件和死亡率方面风险最大。目前,美国临床肿瘤学会和国家综合癌症网络(NCCN)建议使用GA来个性化和指导老年人的临床治疗。然而,由于病情的复杂性以及时间/资源的限制,GA在肿瘤学实践中的广泛使用仍然有限。我们需要一个可以自行管理的单一项目筛查工具来满足临床工作需求。

自评健康(SRH)是一种广泛使用的健康衡量标准,患者被要求根据自己对健康的定义报告其健康状况。它通常使用一个单一问题来衡量,通常措辞为“你是否认为你的健康状况一般”,回答项目为“极好”、“非常好”、“良好”、“一般”或“差”。在居住在社区的老年人中,SRH预测功能受限、认知障碍、医疗保健利用和生存。然而,关于该工具在预测老年癌症患者不良后果方面的效用,数据有限。在这里,我们评估了SRH作为一种筛查工具来确定患有癌症的老年人的虚弱风险和GA识别的损害及其与死亡率的关系。

材料和方法:在UAB癌症和老年复原力评估(CARE)登记中被诊断为癌症的60岁成年人≥在最初咨询时接受了GA检查。我们使用患者报告的结果测量信息系统全球健康量表中的一个项目来衡量SRH,并将反应分为差(差、可)和好(好、非常好和极好)。我们评估了SRH在测量脆弱性和GA损伤(一组七个GA域中的≥2缺陷)方面的诊断性能。我们使用调整混杂因素的COX模型检验了SRH对存活率的影响,探索了脆弱的中介作用。

结果:共纳入603例老年癌症患者,中位年龄69岁。总体而言,45%(n=27.4)的患者报告SRH较差。较差的SRH对识别脆弱(分别为85%和78%)和GA损伤(分别为75%和78%)表现出较高的敏感性和特异性。在COX回归模型中,在调整混杂因素后,SRH差与较差的存活率相关(HR=2.26;95%可信区间1.60-3.18);脆弱在这种观察到的关系中起了69%的中介作用。

结论:自评健康状况可作为一种筛查工具,用于识别患有癌症和GA受损的老年人。较差的SRH与较差的存活率有关,而较差的存活率是由患者基础情况所介导的。

文献来源:Giri S,  Mir N,  Al-Obaidi M,Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with Cancer.Oncologist 2022 02 03;27(1)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800518, encodeId=c3a9180051823, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 13 20:44:17 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866640, encodeId=ad1f1866640a4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Oct 08 13:44:17 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289765, encodeId=791d1289e65a2, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455202, encodeId=f7d414552029b, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1800518, encodeId=c3a9180051823, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 13 20:44:17 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866640, encodeId=ad1f1866640a4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Oct 08 13:44:17 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289765, encodeId=791d1289e65a2, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455202, encodeId=f7d414552029b, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-10-08 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1800518, encodeId=c3a9180051823, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 13 20:44:17 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866640, encodeId=ad1f1866640a4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Oct 08 13:44:17 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289765, encodeId=791d1289e65a2, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455202, encodeId=f7d414552029b, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1800518, encodeId=c3a9180051823, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Oct 13 20:44:17 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866640, encodeId=ad1f1866640a4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Oct 08 13:44:17 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289765, encodeId=791d1289e65a2, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455202, encodeId=f7d414552029b, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Jun 15 13:44:17 CST 2022, time=2022-06-15, status=1, ipAttribution=)]
    2022-06-15 july_977

相关资讯

ESMO Open:老年癌症患者采用免疫抑制剂治疗的副作用风险会更高吗?

据估计,65岁以上人群占新发确诊癌症病例的55%。

Baidu
map
Baidu
map
Baidu
map